- What’s Good for the Goose Is Good for the Government
- March 26, 2025Mind the Gap: Steps Appellate Judges Can Take to Strengthen the Public’s Understanding of the Judiciary
- 2025 Bulletin - First QuarterGENERICally Speaking: A Hatch-Waxman Litigation Bulletin 2025 Q1
- D. Del. Feb. 5, 2025Alcon Inc. v. Padagis Israel Pharms. Ltd.
- D. Del. Jan. 10, 2025Boehringer Ingelheim Pharms. Inc. v. Apotex Inc.
- Fed. Cir. Jan. 10, 2025In re Entresto
- N.D. Ill. Feb. 27, 2025Janssen Prods., L.P. v. EVER Valinject GmbH
- (Fed. Cir. Mar. 28, 2025)Janssen Pharms., Inc. v. Mylan Labs. Ltd.
- D.D.C. Feb. 27, 2025Liquidia Techs., Inc. v. FDA
- D. Del. Feb. 12, 2025Mallinckrodt Pharms. Ireland Ltd. v. Airgas Therapeutics LLC
- Fed. Cir. Mar. 13, 2025Merck Sharp & Dohme B.V. v. Aurobindo Pharma USA, Inc
- D. Del. Jan. 23, 2025Taiho Pharma Co. v. MSN Labs Private Ltd.
- D.D.C. Feb. 13, 2025Vanda Pharms., Inc. v. FDA
- First QuarterNew ANDA Cases
- First QuarterANDA Litigation Settlements
- First QuarterANDA Approvals
- First QuarterGeneric Launches
- The Evolving Role of Internal Corporate Investigations: Why Proactive Oversight Matters More Than Ever
- March 2025Michael Reif: Finding a New Purpose in Personal Injury Law
- March 2025Settlement Highlights Issue of Deliberate Indifference Involving Medical Need in Jails
- March 2025A New York Partnership?
- March 2025Navigating General and Limited Partnerships: Common Pitfalls and How to Avoid Them
- March 2025Show Me the Books! Navigating Minority Shareholder Access to Corporate Information
- January 2025Silent Dangers: The Link Between Depo-Provera, Brain Tumors, and Health Inequities
- Purdue Pharma L.P. v. Accord Healthcare, Inc.
- Teva Branded Pharm. Products R&D, Inc. v. Amneal Pharms. of NY, LLC
- December 2024Board Governance in the Age of AI: Navigating Risks of Note-Taking Tools
- December 2024Navigating AI and Fiduciary Duties: 10 Key Questions for Your Organization
- December 2024Letter from the Editor
- Janssen Pharms., Inc. v. Teva Pharms. USA, Inc.
- Galderma Labs., L.P. v. Lupin Inc.
- Novartis Pharms. Corp. v. MSN Pharms., Inc.
- December 2024A Landmark Victory for Disabled Homeless Veterans: Q&A with the Trial Team
- Fourth QuarterANDA Litigation Settlements
- Melinta Therapeutics, LLC v. Nexus Pharms., Inc.
- November 6, 2024How Recent Patent Damages Precedent May Increase Reasonable Royalty Awards
- Destination Skiing And The DOJ's Mountain Merger Challenge
- Trademark tensions on the track: Court upholds First Amendment protections in Haas v. Steiner
- 2024 Bulletin - Fourth QuarterGENERICally Speaking: A Hatch-Waxman Litigation Bulletin 2024 Q4
- Fourth QuarterNew ANDA Cases
- Exelixis, Inc. v. MSN Labs. Private Ltd.
- October 15, 2024Novartis Pharms. Corp. v. Becerra
- Silvergate Pharms., Inc. v. Bionpharma Inc.
- Fourth QuarterANDA Approvals
- Fourth QuarterGeneric Launches
- September 2024Meet Our New Partner and Trial Advocacy Seminar Keynote Speaker: B. Todd Jones
- September 2024The Wealth Dispute Navigator: Which Profile Are You?
- Astellas Pharma, Inc. v. Sandoz Inc.
- September 18, 2024Astellas Pharma, Inc. v. Sandoz Inc.
- September 2024Q&A with Alan Harter, Founder of Pactolus Private Wealth Management
- September 9, 2024Purdue Pharma L.P v. Accord Healthcare Inc.
- September 4, 2024Exeltis USA, Inc. v. Lupin Ltd.
- Teva Branded Pharm. Products R&D, Inc. v. Deva Holding A.S.
- August 2024Recruiting & Retaining Diverse Attorneys: Building an Inclusive Legal Profession
- Prior Art Takeaways From Fed. Circ. Public Disclosure Ruling
- Third QuarterGeneric Launches
- August 13, 2024Allergan USA, Inc. v. MSN Labs. Private Ltd.
- Novartis Pharms. Corp. v. Becerra
- Playing Dungeons & Dragons Makes Me A Better Lawyer
- Novartis Pharms. Corp. v. Hetero USA Inc.
- Novartis Pharms. Corp. v. MSN Pharms. Inc.
- Pacira Pharms., Inc. v. eVenus Pharms. Labs., Inc.
- August 7, 2024Making a Case for Trade Secret Misappropriation in the US
- Otsuka Pharm. Co., Ltd. v. Lupin Ltd.
- 2024 Bulletin - Third QuarterGENERICally Speaking: A Hatch-Waxman Litigation Bulletin 2024 Q3
- Navigating Copyright Act Section 117 in Software Licensing and Litigation
- Third QuarterANDA Approvals
- Third QuarterANDA Litigation Settlements
- Third QuarterNew ANDA Cases
- "Same as it Ever Was": Why Audio-Video Recordings in and of Trial Court Proceedings Should Not Change the Standard of Appellate Review
- Allergan Holdings Unlimited Co. v. MSN Labs. Private Ltd.
- 2024 Bulletin - Second QuarterGENERICally Speaking: A Hatch-Waxman Litigation Bulletin 2024 Q2
- Making The Whole Truth Public
- Litigation Perspective: Strategies for Licensing Software that Leverages Artificial Intelligence
- June/July 2024A Dive Into Intellectual Property Liability For E-Commerce Platforms
- Amarin Pharma, Inc. v. Hikma Pharms. USA Inc.
- June 2024Robins Kaplan Secures Landmark $7.75 Million Verdict in Aerosol Duster Misuse Case
- June 2024To Seize or Not to Seize: Campus Protests and Police Uses of Force
- June 2024California's Sustainable Insurance Strategy: Balancing Innovation with Industry Challenges
- June 2024A Magnifying Glass on the Notice Prejudice Standard in Massachusetts for Excess Insurers
- June 2024AI’s Impact on Property Insurance Coverage
- June 2024Communicating Your Estate Plan: A Helpful Tool, Not a Fix-All
- September 2024The Wealth Dispute Navigator: Which Profile Are You?
- June 2024Q&A With Anne Paape, Managing Director and Senior Fiduciary Counsel at Cresset
- June 2024Estate Planning to Protect Generational Wealth Transfers: Lessons from The Gilded Age
- Three Alternatives to the USPTO's Terminal Disclaimer Proposal
- Teva Branded Pharm. Products R&D, Inc. v. Amneal Pharms. of NY, LLC
- June 2024Access to Justice Is a Right, Not a Privilege
- May 2024Passing the Buck: The Perils of Oklahoma v. Castro-Huerta
- Second QuarterANDA Litigation Settlements
- Warzone Clash: When Does a Video Game Title Cross the Line Into Trademark Infringement?
